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Background
Cancer is a leading cause of death among dogs worldwide
[1]. The disease results from alterations in expression of
genes that control the cell cycle, including proliferation,
differentiation and programmed cell death [2]. The inter-
est in understanding the molecular aspects of cancer in
humans and dogs is driven by the possibilities of identifi-
cation of novel targets for the development of new antic-
ancer compounds [3]. A molecular tool that has been
used for this purpose is the RNA interference (RNAi)
technique which exploits the mechanism of post-
transcriptional silencing, mediated by molecules of
double-stranded RNA that trigger degradation of com-
plementary mRNAs [4]. However, for the application of
this technique, important aspects must be investigated,
since not all cell strains are susceptible to silencing by
RNAi, and often the intracellular release of the interfer-
ing RNAs has low efficiency [5]. In this work we evalu-
ated the efficiency of RNAi in silencing of topoisomerase
IIA, a target for many anticancer compounds, in the
canine histiocytic sarcoma DH82 cell line.
Materials and methods
DH82 cells at a concentration of 2,4 × 105 cells/well were
cultured in 6 and 24 well plates at 37°C and 5% CO2.
Next, siRNAs (small interfering RNA) designed to target
topoisomerase IIA and glyceraldehyde-3-phosphate dehy-
drogenase (positive control) mRNA were introduced into
cells with the kit N-TER Nanoparticle siRNA Transfec-
tion System (Sigma Aldrich®). The cells were incubated
for 24 hours with a solution of nanoparticles, comprising
siRNA (20-30 nM) complexed to peptides N-TER. After
transfection, the silencing was confirmed by real time
PCR using TaqMan Gene Expression Assays (Applied
Biosystems®). The ΔΔCt method was used for calculating
differences in gene expression levels between the
untransfected and transfected cells. The level of expres-
sion is shown as a fold change positive (induction) or
negative (repression).
Results and discussions
Silencing of topoisomerase IIA (top IIA) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was con-
firmed by obtaining negative fold change. Following
transfection in 6-well plates, it was obtained a fold change
of -2,56 and -1,35 for the top IIA and GAPDH genes,
respectively. The level of silencing of type IIA decreases
after incubation of the transfected cells in the absence of
siRNA, as demonstrated by reduced values of the fold
change for -0,95 and -0,82 after 24 and 48 hours of incu-
bation, respectively. The transfection in 6 and 24 well
plates resulted in silencing of the top IIA of -2,56 and
-0,73. The use of 24 well plate for transfection, possibly
facilitates the internalization of siRNA/peptide complex by
cells. The increased concentration of siRNA from 20 to
30 nM did not result in increased silencing of the top IIA.
Conclusions
The lineage DH82 demonstrated susceptibility to silen-
cing mediated by RNAi. The use of RNAi technique in
this cell lineage when performed under ideal conditions
of transfection was efficient, allowing the use of this
model as a tool to assist in the identification of new tar-
gets for the development of new anticancer drugs.
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